RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ultimovacs A Stock

Ultimovacs A Net Income 2024

Ultimovacs A Net Income

-83.68 M NOK

Ticker

ULTI.OL

ISIN

NO0010851603

WKN

A2PKSD

In 2024, Ultimovacs A's profit amounted to -83.68 M NOK, a -55.78% increase from the -189.24 M NOK profit recorded in the previous year.

The Ultimovacs A Net Income history

YEARNET INCOME (undefined NOK)
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-

Ultimovacs A Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ultimovacs A, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ultimovacs A from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ultimovacs A’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ultimovacs A. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ultimovacs A’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ultimovacs A’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ultimovacs A’s growth potential.

Ultimovacs A Revenue, EBIT and net profit per share

DateUltimovacs A RevenueUltimovacs A EBITUltimovacs A Net Income
2026e0 undefined-112.2 M undefined-14.03 M undefined
2025e44.37 M undefined-76.5 M undefined-37.89 M undefined
2024e0 undefined-154.53 M undefined-83.68 M undefined
20230 undefined-215.74 M undefined-189.24 M undefined
20220 undefined-183.63 M undefined-167.79 M undefined
20210 undefined-163.83 M undefined-164.72 M undefined
20200 undefined-124.15 M undefined-120.55 M undefined
20190 undefined-66.22 M undefined-61.17 M undefined
20180 undefined-56.52 M undefined-55.28 M undefined
20170 undefined-33.39 M undefined-32.83 M undefined
20160 undefined-33.04 M undefined-28.98 M undefined
20158.43 M undefined-21.11 M undefined-20.69 M undefined

Ultimovacs A stock margins

The Ultimovacs A margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ultimovacs A. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ultimovacs A.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ultimovacs A's sales revenue. A higher gross margin percentage indicates that the Ultimovacs A retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ultimovacs A's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ultimovacs A's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ultimovacs A's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ultimovacs A. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ultimovacs A's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ultimovacs A Margin History

Ultimovacs A Gross marginUltimovacs A Profit marginUltimovacs A EBIT marginUltimovacs A Profit margin
2026e0 %0 %0 %
2025e0 %-172.41 %-85.4 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %-250.44 %-245.41 %

Ultimovacs A Aktienanalyse

What does Ultimovacs A do?

Ultimovacs ASA is a Norwegian biotech company specializing in the development of cancer immunotherapies. The company was founded in 2011 by Øyvind Kongstun Arnesen and Gustav Gaudernack, and is headquartered in Oslo, Norway. Ultimovacs ASA's history began with the discovery of a unique Pep-antigene concept by founder Gustav Gaudernack. Over the years, the company has worked extensively on the development of innovative cancer immunotherapies based on stimulation of the body's immune system. Ultimovacs has developed a proprietary platform technology called UV1, based on the simple idea that the immune system can respond to certain structures known as peptides. The UV1 technology is based on synthetic peptides containing specific antigens that are widespread in many different types of cancer. Ultimovacs ASA's business model focuses on developing and bringing innovative cancer therapies to market. The company has three main research programs focusing on different types of cancer: lung cancer, mesothelioma, and prostate cancer. The lung cancer program is the most advanced and is currently in Phase IIb clinical trials. The basis for this program is the UV1 vaccine administered in combination with a checkpoint inhibitor therapy. The combination therapy was developed to boost the body's defenses against cancer growth and inhibit tumor growth. Ultimovacs' mesothelioma program was in the preclinical phase until recently, but has recently been approved to enter Phase I/II clinical trials. The mesothelioma therapy is also based on the UV1 platform, which was developed in a personalized form for this rare type of cancer. Ultimovacs' prostate cancer program is still in the preclinical phase, but promising results have already been obtained. The company has applied its UV1 technology in personalized therapy to identify and target specific antigens in prostate cancer patients. Ultimovacs ASA has also formed partnerships with other companies and institutions to combine its research and development activities. The company has collaborations with French pharmaceutical company Ipsen and a research group at the University of Oslo, among others. Overall, Ultimovacs ASA has a clear focus on developing cancer immunotherapies based on stimulating the body's own immune system. The company has developed a proprietary UV1 technology that allows it to quickly and effectively develop personalized therapies for different types of cancer. With its intensive research and collaboration with other companies and institutions, Ultimovacs will continue to strive to improve the state of immunooncology in cancer treatment. The answer is Ultimovacs ASA is a Norwegian biotech company specializing in cancer immunotherapy development. Ultimovacs A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Ultimovacs A's Profit Margins

The profit margins of Ultimovacs A represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Ultimovacs A's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Ultimovacs A's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Ultimovacs A's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Ultimovacs A’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Ultimovacs A stock

How much profit has Ultimovacs A made this year?

Ultimovacs A has made -83.68 M NOK this year.

How has the profit developed compared to last year?

The profit has increased by -55.78% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Ultimovacs A publish its earnings?

Ultimovacs A publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Ultimovacs A?

The profits of Ultimovacs A are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Ultimovacs A?

You can learn more about the earnings of Ultimovacs A by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Ultimovacs A pay?

Over the past 12 months, Ultimovacs A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ultimovacs A is expected to pay a dividend of 0 NOK.

What is the dividend yield of Ultimovacs A?

The current dividend yield of Ultimovacs A is .

When does Ultimovacs A pay dividends?

Ultimovacs A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ultimovacs A?

Ultimovacs A paid dividends every year for the past 0 years.

What is the dividend of Ultimovacs A?

For the upcoming 12 months, dividends amounting to 0 NOK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ultimovacs A located?

Ultimovacs A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ultimovacs A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ultimovacs A from 11/6/2024 amounting to 0 NOK, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Ultimovacs A pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of Ultimovacs A in the year 2023?

In the year 2023, Ultimovacs A distributed 0 NOK as dividends.

In which currency does Ultimovacs A pay out the dividend?

The dividends of Ultimovacs A are distributed in NOK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ultimovacs A

Our stock analysis for Ultimovacs A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ultimovacs A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.